S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:TCRR

TCR2 Therapeutics Competitors

$24.06
-1.67 (-6.49 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.25
Now: $24.06
$25.96
50-Day Range
$25.73
MA: $28.48
$33.99
52-Week Range
$5.84
Now: $24.06
$35.86
Volume502,818 shs
Average Volume445,229 shs
Market Capitalization$804.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13

Competitors

TCR2 Therapeutics (NASDAQ:TCRR) Vs. RVMD, NK, EDIT, NSTG, SRNE, and ALVR

Should you be buying TCRR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to TCR2 Therapeutics, including Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), and AlloVir (ALVR).

Revolution Medicines (NASDAQ:RVMD) and TCR2 Therapeutics (NASDAQ:TCRR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Profitability

This table compares Revolution Medicines and TCR2 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
TCR2 TherapeuticsN/A-35.51%-34.02%

Institutional and Insider Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 82.1% of TCR2 Therapeutics shares are owned by institutional investors. 28.0% of TCR2 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Revolution Medicines and TCR2 Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21

TCR2 Therapeutics has lower revenue, but higher earnings than Revolution Medicines.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Revolution Medicines and TCR2 Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines01402.80
TCR2 Therapeutics00703.00

Revolution Medicines presently has a consensus price target of $50.75, suggesting a potential upside of 19.55%. TCR2 Therapeutics has a consensus price target of $39.2857, suggesting a potential upside of 63.28%. Given TCR2 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TCR2 Therapeutics is more favorable than Revolution Medicines.

Summary

TCR2 Therapeutics beats Revolution Medicines on 6 of the 10 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and TCR2 Therapeutics (NASDAQ:TCRR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Institutional & Insider Ownership

9.4% of NantKwest shares are owned by institutional investors. Comparatively, 82.1% of TCR2 Therapeutics shares are owned by institutional investors. 71.7% of NantKwest shares are owned by insiders. Comparatively, 28.0% of TCR2 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for NantKwest and TCR2 Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
TCR2 Therapeutics00703.00

NantKwest currently has a consensus price target of $18.00, suggesting a potential downside of 30.10%. TCR2 Therapeutics has a consensus price target of $39.2857, suggesting a potential upside of 63.28%. Given TCR2 Therapeutics' higher probable upside, analysts plainly believe TCR2 Therapeutics is more favorable than NantKwest.

Profitability

This table compares NantKwest and TCR2 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
TCR2 TherapeuticsN/A-35.51%-34.02%

Valuation & Earnings

This table compares NantKwest and TCR2 Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21

TCR2 Therapeutics has lower revenue, but higher earnings than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than TCR2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Comparatively, TCR2 Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.

Summary

TCR2 Therapeutics beats NantKwest on 8 of the 12 factors compared between the two stocks.

TCR2 Therapeutics (NASDAQ:TCRR) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Profitability

This table compares TCR2 Therapeutics and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TCR2 TherapeuticsN/A-35.51%-34.02%
Editas Medicine-99.62%-26.74%-16.38%

Volatility & Risk

TCR2 Therapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for TCR2 Therapeutics and Editas Medicine, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TCR2 Therapeutics00703.00
Editas Medicine34302.00

TCR2 Therapeutics currently has a consensus price target of $39.2857, indicating a potential upside of 63.28%. Editas Medicine has a consensus price target of $49.2222, indicating a potential upside of 21.96%. Given TCR2 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TCR2 Therapeutics is more favorable than Editas Medicine.

Insider & Institutional Ownership

82.1% of TCR2 Therapeutics shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 28.0% of TCR2 Therapeutics shares are owned by insiders. Comparatively, 0.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares TCR2 Therapeutics and Editas Medicine's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06

TCR2 Therapeutics has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than TCR2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

TCR2 Therapeutics beats Editas Medicine on 8 of the 13 factors compared between the two stocks.

TCR2 Therapeutics (NASDAQ:TCRR) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Volatility and Risk

TCR2 Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Institutional & Insider Ownership

82.1% of TCR2 Therapeutics shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 28.0% of TCR2 Therapeutics shares are held by insiders. Comparatively, 4.2% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares TCR2 Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TCR2 TherapeuticsN/A-35.51%-34.02%
NanoString Technologies-53.47%-68.96%-24.15%

Analyst Ratings

This is a summary of recent recommendations for TCR2 Therapeutics and NanoString Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TCR2 Therapeutics00703.00
NanoString Technologies01502.83

TCR2 Therapeutics currently has a consensus price target of $39.2857, indicating a potential upside of 63.28%. NanoString Technologies has a consensus price target of $63.00, indicating a potential upside of 3.26%. Given TCR2 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TCR2 Therapeutics is more favorable than NanoString Technologies.

Earnings & Valuation

This table compares TCR2 Therapeutics and NanoString Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21
NanoString Technologies$125.57 million21.41$-40,700,000.00($1.93)-31.61

NanoString Technologies has higher revenue and earnings than TCR2 Therapeutics. NanoString Technologies is trading at a lower price-to-earnings ratio than TCR2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

TCR2 Therapeutics beats NanoString Technologies on 8 of the 13 factors compared between the two stocks.

TCR2 Therapeutics (NASDAQ:TCRR) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Valuation & Earnings

This table compares TCR2 Therapeutics and Sorrento Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21
Sorrento Therapeutics$31.43 million78.73$-292,070,000.00($2.12)-4.16

TCR2 Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. TCR2 Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TCR2 Therapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, meaning that its share price is 170% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for TCR2 Therapeutics and Sorrento Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TCR2 Therapeutics00703.00
Sorrento Therapeutics00403.00

TCR2 Therapeutics presently has a consensus target price of $39.2857, suggesting a potential upside of 63.28%. Sorrento Therapeutics has a consensus target price of $28.75, suggesting a potential upside of 226.33%. Given Sorrento Therapeutics' higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than TCR2 Therapeutics.

Profitability

This table compares TCR2 Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TCR2 TherapeuticsN/A-35.51%-34.02%
Sorrento Therapeutics-698.01%-314.06%-43.60%

Institutional & Insider Ownership

82.1% of TCR2 Therapeutics shares are held by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are held by institutional investors. 28.0% of TCR2 Therapeutics shares are held by company insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

TCR2 Therapeutics beats Sorrento Therapeutics on 7 of the 12 factors compared between the two stocks.

AlloVir (NASDAQ:ALVR) and TCR2 Therapeutics (NASDAQ:TCRR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Institutional and Insider Ownership

32.1% of AlloVir shares are owned by institutional investors. Comparatively, 82.1% of TCR2 Therapeutics shares are owned by institutional investors. 1.0% of AlloVir shares are owned by company insiders. Comparatively, 28.0% of TCR2 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares AlloVir and TCR2 Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/AN/AN/AN/A
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21

Analyst Recommendations

This is a summary of recent ratings and price targets for AlloVir and TCR2 Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AlloVir00403.00
TCR2 Therapeutics00703.00

AlloVir presently has a consensus target price of $48.75, suggesting a potential upside of 41.18%. TCR2 Therapeutics has a consensus target price of $39.2857, suggesting a potential upside of 63.28%. Given TCR2 Therapeutics' higher probable upside, analysts plainly believe TCR2 Therapeutics is more favorable than AlloVir.

Profitability

This table compares AlloVir and TCR2 Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AlloVirN/AN/AN/A
TCR2 TherapeuticsN/A-35.51%-34.02%

Summary

TCR2 Therapeutics beats AlloVir on 4 of the 6 factors compared between the two stocks.


TCR2 Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.